QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 deal-dispatch-need-ma-approval-fcc-chair-explains-how-to-get-it

The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desper...

 anebulo-pharmaceuticals-weighs-going-private-as-board-reviews-strategic-alternatives

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people s...

 maxim-group-downgrades-anebulo-pharmaceuticals-to-hold

Maxim Group analyst Michael Okunewitch downgrades Anebulo Pharmaceuticals (NASDAQ:ANEB) from Buy to Hold.

 anebulo-pharmaceuticals-approves-plan-for-reverse-stock-spilt-of-not-less-than-1-for-2500-and-not-more-than-1-for-7500-as-proposed-stockholders-will-receive-350-per-pre-spilt-share

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suff...

 anebulo-pharma-proposes-reverse-stock-split-and-350-cash-out-offer-to-go-private

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suff...

 maxim-group-maintains-buy-on-anebulo-pharmaceuticals-lowers-price-target-to-3

Maxim Group analyst Michael Okunewitch maintains Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy and lowers the price targe...

 anebulo-pharmaceuticals-q3-eps-004-beats-005-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate ...

 anebulo-pharmaceuticals-q2-2025-gaap-eps-009-misses-008-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION